...
首页> 外文期刊>Expert Review of Molecular Diagnostics >Use of the BRET 7TM receptor/beta-arrestin assay in drug discovery and screening.
【24h】

Use of the BRET 7TM receptor/beta-arrestin assay in drug discovery and screening.

机译:BRET 7TM受体/β-抑制蛋白在药物发现和筛选中的用途。

获取原文
获取原文并翻译 | 示例

摘要

To perform functional cell-based screening assays on seven-transmembrane (7TM) receptors, also known as G-protein coupled receptors, at least three distinct assays are currently needed to screen for G(alphas), G(alphai/0) or G(alphaq/11) signaling receptors. Therefore, there has long been a desire for a universal screening assay that could be used to screen all 7TM receptors independent of their signaling pathway. The receptor/beta-arrestin interaction is common to virtually all 7TM receptors. Therefore, an assay based on this interaction should achieve just that. Bioluminescence resonance energy transfer technology can be used to measure the receptor/beta-arrestin interaction in living cells but due to various technical and biological reasons, the use of the technology for compound screening has been limited. The recent development of beta-arrestin mutants that significantly improve the assay signal, in combination with new improved instrumentation, has transformed bioluminescence resonance energy transfer technology from being a highly specialized research tool in molecular pharmacology to a more drug screening-friendly technique that is useful in an industrial setting.
机译:要对七跨膜(7TM)受体(也称为G蛋白偶联受体)进行基于细胞的功能性筛选测定,目前至少需要三种不同的测定方法来筛选G(alphas),G(alphai / 0)或G (alphaq / 11)信号受体。因此,长期以来人们一直希望有一种通用的筛选测定法,该方法可以用于筛选所有7TM受体而与它们的信号传导途径无关。受体/β-arrestin相互作用实际上是所有7TM受体共有的。因此,基于这种相互作用的测定应能达到目的。生物发光共振能量转移技术可用于测量活细胞中的受体/β-arrestin相互作用,但由于各种技术和生物学原因,限制了该技术用于化合物筛选的用途。 β-arrestin突变体的最新发展与新改良的仪器相结合,可显着改善测定信号,已将生物发光共振能量转移技术从分子药理学中的高度专业化研究工具转变为对药物筛选更为友好的技术,非常有用在工业环境中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号